Skip to content
ppharmaranks
Menu
Class IIOngoing

Niacin Extended-release Tablets recall

FDA recall D-0096-2026 · initiated Oct 10, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Oct 29, 2025How we research

Lannett Company Inc. recalled Niacin Extended-release Tablets in Oct 2025 — an FDA Class II recall (D-0096-2026) because Failed Dissolution Specifications.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Failed Dissolution Specifications

Wrong strength, or it did not keep

The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot, expiry: 21264027A, Exp 10/30/2025; 22266446A, Exp 12/31/2025; 22266901A, Exp 02/28/2026; 22267553A, 22267554A, Exp 03/31/2026; 22267555A, Exp 02/28/2026; 22267992A, Exp 04/30/2026; 22267993A, 22267994A, Exp 05/31/2026

Quantity recalled: 46,848 90-count bottles

Details

Product
Niacin Extended-release Tablets, USP, 1,000 mg, Rx Only, 90 Tablets per bottle, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC: 62175-322-46
Recalling company
Lannett
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Oct 10, 2025
FDA report date
Oct 29, 2025
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Niacin Extended-release Tablets recalled?
Lannett Company Inc. recalled Niacin Extended-release Tablets in Oct 2025 — an FDA Class II recall (D-0096-2026) because Failed Dissolution Specifications. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Niacin Extended-release Tablets recalled?
Per the FDA enforcement record, the reason for recall D-0096-2026 was: Failed Dissolution Specifications
Is a recalled Niacin Extended-release Tablets dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Niacin Extended-release Tablets are affected?
Distributed: Nationwide in the USA. The recall covers these lots — Lot, expiry: 21264027A, Exp 10/30/2025; 22266446A, Exp 12/31/2025; 22266901A, Exp 02/28/2026; 22267553A, 22267554A, Exp 03/31/2026; 22267555A, Exp 02/28/2026; 22267992A, Exp 04/30/2026; 22267993A, 22267994A, Exp 05/31/2026. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0096-2026.

Source: openFDA Drug Enforcement record D-0096-2026

← All drug recalls